Dr. Nathalie Ganne-Carrié: Exploration and Clinical Practice of Biomarkers for Hepatocellular Carcinoma

Dr. Nathalie Ganne-Carrié: Exploration and Clinical Practice of Biomarkers for Hepatocellular Carcinoma

2024.02.01
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide. Although the prognosis for HCC patients is generally poor, if diagnosed early, the 5-year survival rate can exceed 70%. Currently, the diagnosis of HCC without pathological evidence mainly relies on analyzing serum alpha-fetoprotein (AFP) levels and radiological diagnosis. Therefore, exploring early diagnostic biomarkers for HCC is of great clinical significance. In recent years, with advancements in genomics and proteomics, and the rapid development of biomarker detection technologies, numerous new biomarkers have been identified, promising to improve early diagnosis of HCC. At the recently concluded 17th annual meeting of the International Liver Cancer Association (ILCA), Dr. Nathalie Ganne-Carrié from the University Hospital of Paris Seine-Saint-Denis gave a special report on the progress of early diagnostic biomarkers for HCC. We invited Dr. Nathalie Ganne-Carrié for an in-depth interview. Here's a summary for our readers.
Dr. Qiang Gao: The Complexity and Diversity of Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma

Dr. Qiang Gao: The Complexity and Diversity of Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma

2024.01.31
 Intrahepatic cholangiocarcinoma (ICC) refers to adenocarcinoma originating from the epithelium of secondary bile ducts and their branches, accounting for 10%-15% of primary malignant tumors in the liver. In recent years, the incidence of ICC has been rising significantly, garnering increasing clinical attention. While ICC and hepatocellular carcinoma (HCC) both belong to primary liver cancers, they have distinct biological characteristics. The complex disease characteristics and prognosis pose significant challenges for ICC's clinical treatment. From September 7-9, 2023, the 17th annual meeting of the International Liver Cancer Association (ILCA) was grandly held in Amsterdam, Netherlands. At the conference, Dr. Qiang Gao from Zhongshan Hospital, Fudan University, China, shared recent advancements in the study of tumor-immune interactions in ICC. This article compiles an in-depth interview with Dr. Gao for our readers.